CMS-Supported Clinical Data Collection Worth The Cost – Tunis
This article was originally published in The Gray Sheet
Executive Summary
CMS will seek public comments early this year on criteria for deciding which national coverage policies should include data collection requirements
You may also be interested in...
FDA Needs Better Postmarket Data, Not More Postmarket Authority – Schultz
FDA should establish a permanent network of hospitals to collect device postmarket data while lowering the evidence standard for market approval, Harvard Clinical Research Institute Chief Scientific Officer Richard Kuntz, MD, suggests
FDA Needs Better Postmarket Data, Not More Postmarket Authority – Schultz
FDA should establish a permanent network of hospitals to collect device postmarket data while lowering the evidence standard for market approval, Harvard Clinical Research Institute Chief Scientific Officer Richard Kuntz, MD, suggests
AdvaMed, MDMA Prepare Comments On CMS Data-Collection Guidance
AdvaMed has formed a working group to make recommendations to CMS on how the agency's process for writing clinical study requirements into coverage decisions could be more efficient and predictable